SCHEMBL23046843

SCHEMBL23046843

COC(=O)c1ccc2nc(CCl)n(CC3CCC3)c2c1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ACSS2 Q9NR19 1/20 0.44
▸ CNR2 P34972 8/20 0.44
▸ CNR1 P21554 3/20 0.44
▸ PTGER4 P35408 1/20 0.44
▸ P2RX3 P56373 3/20 0.42
▸ NLRP3 Q96P20 1/20 0.42
▸ P2RX2 Q9UBL9 1/20 0.42
▸ DRD2 P14416 1/20 0.42
▸ TBXA2R P21731 1/20 0.42
▸ GLP1R P43220 1/20 0.42
▸ KDM4E B2RXH2 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ RXFP1 Q9HBX9 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27111001 0.88 ACSS2 (0.44) ACSS2CNR2CNR1PTGER4DRD2
SCHEMBL30686442 0.88 ACSS2 (0.44) ACSS2CNR2CNR1PTGER4DRD2
SCHEMBL29946132 0.87 GLP1R (0.45) ACSS2CNR2CNR1PTGER4DRD2
SCHEMBL30911935 0.87 GLP1R (0.45) ACSS2CNR2CNR1PTGER4DRD2
SCHEMBL25321929 0.87 GLP1R (0.45) ACSS2CNR2CNR1PTGER4DRD2
SCHEMBL30474102 0.87 GLP1R (0.45) ACSS2CNR2CNR1PTGER4DRD2
SCHEMBL20279928 0.86 ALDH1A1 (0.44) ACSS2GLP1RALDH1A1
SCHEMBL20288032 0.86 ALDH1A1 (0.44) ACSS2GLP1RALDH1A1
SCHEMBL30513859 0.86 ALDH1A1 (0.44) ACSS2GLP1RALDH1A1
SCHEMBL29945929 0.86 ALDH1A1 (0.44) ACSS2GLP1RALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4562006-A1 N-HETEROCYLIC GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE Carmot Therapeutics, Inc. (US) 2025-06-04 — — EP disclosed
CN-119923395-A N-heterocyclic GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods of use thereof 卡莫特医疗有限公司 2025-05-02 — — CN disclosed
WO-2024026338-A1 N-HETEROCYLIC GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE CARMOT THERAPEUTICS, INC. (US) 2024-02-01 — — WO disclosed
WO-2024026338-A1 N-HETEROCYLIC GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE CARMOT THERAPEUTICS, INC. (US) 2024-02-01 — — WO disclosed
US-10934279-B2 GLP-1 receptor agonists and uses thereof PFIZER INC. (US) 2021-03-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10934279-B2 GLP-1 receptor agonists and uses thereof GLP1R, GIPR, GCGR ACSS2 1613/4885CNR2 1076/4885CNR1 616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback